Rhupus Syndrome and Efficacy of Etanercept Treatment

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yang Beibei
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1

Exclusion Criteria:

• those who had participated in other studies